ADVFN - Advanced Financial Network.
HOME» NYSE » N » NVS Stock Price » NVS Stock News

Novartis Share News

 Novartis Ag Basel Stock Price
NVS Stock Price
 Novartis Ag Basel Stock Chart
NVS Stock Chart
 Novartis Ag Basel Stock News
NVS Stock News
 Novartis Ag Basel Company Information
NVS Company Information
 Novartis Ag Basel Stock Trades
NVS Stock Trades

Novartis: Pasireotide Works Well In Acromegaly Trial

By Marta Falconi Of DOW JONES NEWSWIRES ZURICH -(Dow Jones)- An experimental drug by Novartis (NVS) for the treatment of a rare endocrine disorder is working better than the standard of care in a late-stage clinical trial, the company said Monday. Patients treated with pasireotide LAR, or SOM230, were 63% more likely to achieve control of their disease than those treated with Novartis' Sandostatin LAR, or octreotide, the study showed. The safety profile of pasireotide LAR was similar to that of octreotide LAR, known under the brand name Sandostatin, with the exception of a higher degree of hyperglycemia, Novartis said. "The positive results seen in the Phase III trial point to the potential role of pasireotide LAR in treating patients with acromegaly, a condition for which there remains an unmet need," said Herve Hoppenot, president of Novartis Oncology, in a statement. "These findings are welcome news as we continue our research efforts to discover treatments for patients with pituitary-related conditions." Acromegaly, a rare endocrine disorder caused by excess growth hormone, can result in enlarged hands, feet and internal organs, and increased risk of death. Novartis said the data were presented at the 15th International Congress of Endocrinology and 14th European Congress of Endocrinology meeting in Florence, Italy. The medical meeting runs from May 5 to May 9. -By Marta Falconi, Dow Jones Newswires; +41 43 443 8043; marta.falconi@dowjones.com

Stock News for Novartis (NVS)
DateTimeHeadline
04/10/201412:25:40Zurich Stocks See Gains
04/09/201408:34:24Novartis Names New Alcon, Sandoz Division Heads -- Update
04/09/201402:50:35Novartis Names New Alcon, Sandoz Division Heads
04/03/201417:12:35ADR Shares End Lower; Vodafone Shares Active
04/02/201416:55:18ADR Shares End Higher; Noah Education Shares Active
03/31/201417:16:48ADR Shares End Higher; ING, Novartis Shares Active
03/31/201412:29:09EUROPE MARKETS: European Stocks End Mixed On Inflation Jitters
03/31/201411:07:25Supreme Court to Review Teva Appeal in Copaxone Patent Case
03/31/201410:29:55EUROPE MARKETS: European Stocks Push Higher After Weak Inflation
03/31/201406:22:12EUROPE MARKETS: European Stocks Pare Gains After Weak Inflation...
03/31/201404:55:55EUROPE MARKETS: European Stocks Firm Ahead Of Inflation Data
03/31/201403:25:12Novartis Heart Failure Pill Trial Ends Early on Positive Result
03/26/201413:54:19EUROPE MARKETS: Europe Stocks Higher As ECB Stokes Stimulus Hopes
03/22/201404:16:47Novartis Chairman Stresses Need for R&D Investment
03/21/201413:26:03Glaxo Wins Battle Over Asthma Drug
03/14/201417:12:21ADR Shares End Lower; GlaxoSmithKline Shares Active
03/14/201412:10:09HSBC Taps Symonds as Chairman of European Retail Unit
03/14/201411:55:38HSBC Appoints Former Novartis CFO as Chairman of European Retail...
03/07/201408:12:10EUROPE MARKETS: European Stocks Head For Weekly Loss Ahead Of...
02/26/201412:40:17Novartis to Shut U.K. Plant, Cut 361 Jobs

Novartis and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad